RECKITT BENCKISER HEALTHCARE (UK) LIMITED

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Compound Sodium Alginate Double Action Chewable Tablets 4-hour Esophageal PH Study in GERD Patients

Phase 3

Completed

Conditions: Gastroesophageal Reflux Disease

Interventions: Drug: Sodium Alginate Double Action Tablets
Drug: Placebo

First Posted Date: 2013-06-07

Last Posted Date: 2024-11-08

Lead Sponsor: Reckitt Benckiser Healthcare (UK) Limited

Target Recruit Count: 45

Registration Number: NCT01872897

Locations: 🇨🇳
RB Investigational Sites, Shanghai, China

Compound Sodium Alginate Double Action Chewable Tablet Symptomatic Relief Study

Phase 3

Completed

Conditions: Gastroesophageal Reflux Disease
Dyspepsia

Interventions: Drug: Compound Sodium Alginate Double Action Chewable Tablets
Drug: Matching placebo tablets

First Posted Date: 2013-06-05

Last Posted Date: 2024-11-08

Lead Sponsor: Reckitt Benckiser Healthcare (UK) Limited

Target Recruit Count: 1107

Registration Number: NCT01869491

Locations: 🇨🇳
RB Investigational Sites, Shanghai, China

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy